Hypothalamic obesity (HyOb) develops when brain damage or conditions like Prader-Willi syndrome disrupt the hypothalamus, impairing hunger and energy regulation. Traditional calorie-based weight-loss ...

Obesity associated with hypothalamic dysfunction was initially described in patients with craniopharyngioma. Hypothalamic obesity may also result from brain radiation, infection (eg, tuberculosis), ...

Before GLP-1 agonists became the blockbuster obesity drugs many people know and use today, Rhythm Pharmaceuticals was researching molecules that take a similar approach but for a different target. The ...

Setmelanotide treatment over a 16-week period leads to a consistent decrease in both bodyweight and hunger among patients with hypothalamic obesity, according to the results of the first known study ...

RYTM soared 36.6% after positive Phase II data for oral bivamelagon in acquired hypothalamic obesity. Bivamelagon cut BMI by up to 9.3% in patients with acquired hypothalamic obesity. Rhythm plans FDA ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Setmelanotide reduced BMI by a mean 18% for children and ...

Shares of Rhythm Pharmaceuticals RYTM rallied 17.1% on Monday after the company announced that it has met the primary endpoint in a late-stage study of its candidate, setmelanotide, for treating ...

Credit: Rhythm Pharmaceuticals. The melanocortin 4 receptor agonist setmelanotide is now FDA approved for weight management in adults and children with acquired hypothalamic obesity. Clinical trial ...

In patients with acquired hypothalamic obesity, treatment with setmelanotide for 2.5 years was associated with sustained ...

A Prescription Drug User Fee Act target date of December 20, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) ...

New research reveals how extracellular matrix (ECM) buildup in the brain’s hypothalamus leads to insulin resistance, paving the way for innovative therapies targeting obesity and diabetes. Study: ...